Literature DB >> 25167684

Prevalence and clinical predictors of reverse remodeling in patients with dilated cardiomyopathy.

Michael Arad, Tamar Nussbaum, Ido Blechman, Micha S Feinberg, Nira Koren-Morag, Yael Peled, Dov Freimark.   

Abstract

BACKGROUND: Contemporary therapiesimprove prognosis and may restore left ventricular (LV) sizeand function.
OBJECTIVES: To examine the prevalence, clinical features and therapies associated with reverse remodeling (RR) in dilated cardiomyopathy (DCM).
METHODS: The study group comprised 188 DCM patients who had undergone two echo examinations at least 6 months apart. RR was defined as increased LV ejection fraction (LVEF) by > or = 10% concomitant with > or = 10% decreased LV end-diastolic dimension.
RESULTS: RR occurred in 50 patients (26%) and was associated with significantly reduced end-systolic dimension, left atrial size, grade of mitral regurgitation, and pulmonary artery pressure. NYHA class improved in the SRR group. RR was less common in familial DCM and a long-standing disease and was more prevalent in patients with prior exposure to chemotherapy. Recent-onset disease, Iower initial LVEF and normal electrocardiogram were identified as independent predictors of RR. Beta-blocker dose wasrelated to improved LVEF but not to RR. Over a mean follow-up of 23 months, 16 patients (12%) from the 'no-RR' group died or underwent heart transplantation compared to none from the RR group (P < 0.01).
CONCLUSIONS: Contemporary therapies led to an an improvement in the condition of a considerable number of DCM patients. A period of close observation while optimizing medical therapy should be considered before deciding on invasive procedures.

Entities:  

Mesh:

Year:  2014        PMID: 25167684

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


  1 in total

1.  Clinical Determinants and Prognosis of Left Ventricular Reverse Remodelling in Non-Ischemic Dilated Cardiomyopathy.

Authors:  Carles Díez-López; Joel Salazar-Mendiguchía; Elena García-Romero; Lara Fuentes; Josep Lupón; Antoni Bayés-Genis; Nicolás Manito; Marta de Antonio; Pedro Moliner; Elisabet Zamora; Pablo Catalá-Ruiz; Miguel Caínzos-Achirica; Josep Comín-Colet; José González-Costello
Journal:  J Cardiovasc Dev Dis       Date:  2022-01-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.